Research Analysts Issue Forecasts for Tiziana Life Sciences PLC’s FY2021 Earnings (NASDAQ:TLSA)


Share on StockTwits

Tiziana Life Sciences PLC (NASDAQ:TLSA) – Stock analysts at Zacks Investment Research issued their FY2021 earnings estimates for shares of Tiziana Life Sciences in a research note issued on Monday, April 12th. Zacks Investment Research analyst J. Vandermosten anticipates that the company will earn ($0.30) per share for the year. Zacks Investment Research has a “Not Rated” rating and a $7.50 price target on the stock. Zacks Investment Research also issued estimates for Tiziana Life Sciences’ FY2022 earnings at ($0.28) EPS.

Separately, B. Riley began coverage on shares of Tiziana Life Sciences in a research note on Tuesday, December 22nd. They set a “buy” rating and a $8.00 price objective for the company.

Tiziana Life Sciences stock opened at $2.52 on Thursday. The firm has a 50-day moving average of $2.89 and a 200-day moving average of $3.17. Tiziana Life Sciences has a one year low of $1.04 and a one year high of $12.17. The company has a market cap of $161.83 million, a price-to-earnings ratio of -84.00 and a beta of 1.41.

A number of large investors have recently modified their holdings of TLSA. Credit Suisse AG acquired a new stake in Tiziana Life Sciences in the 4th quarter valued at about $40,000. Golden Green Inc. bought a new position in Tiziana Life Sciences in the 4th quarter valued at about $44,000. Ausdal Financial Partners Inc. raised its holdings in Tiziana Life Sciences by 72.4% in the 4th quarter. Ausdal Financial Partners Inc. now owns 26,200 shares of the company’s stock valued at $53,000 after acquiring an additional 11,000 shares during the period. Virtu Financial LLC bought a new position in Tiziana Life Sciences in the 4th quarter valued at about $67,000. Finally, Wells Fargo & Company MN raised its holdings in Tiziana Life Sciences by 230.4% in the 4th quarter. Wells Fargo & Company MN now owns 35,850 shares of the company’s stock valued at $72,000 after acquiring an additional 25,000 shares during the period.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.

Recommended Story: Calculating net profit and net profit margin ratio

Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.